ストックスクリーナーアプリを入手
2.68
11.20%
0.27
Outlook Therapeutics Inc (OTLK) 最新ニュース
Certain Warrants of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-AUG-2025. - MarketScreener
Will Outlook Therapeutics (OTLK) Stocks Rise? - StocksToTrade
Outlook Therapeutics Reports Q3 Revenue - AOL.com
Outlook Therapeutics Inc. Recovery Likely Here’s What Data ShowsJuly 2025 Summary & High Win Rate Trade Alerts - classian.co.kr
Analysts’ Top Healthcare Picks: Outlook Therapeutics (OTLK), Pfizer (PFE) - The Globe and Mail
Can Outlook Therapeutics Inc. Escape Recent Bear ChannelJuly 2025 Levels & Target Return Focused Stock Picks - 선데이타임즈
Can Outlook Therapeutics Inc. Overcome Bearish SentimentEarnings Overview Summary & Low Drawdown Trading Techniques - newsyoung.net
Outlook Therapeutics (OTLK.O) Surges 17.7%—What’s Fueling the Intraday Spike? - AInvest
Outlook Therapeutics Inc. (OTLK) Soars 11.97% on FDA Decision Anticipation - AInvest
Outlook Therapeutics Posts Q3 2025 Loss Amid High Operating Costs—Market Impact and Earnings Backtest Insights - AInvest
Navigating Trade Turbulence: Outlook Therapeutics Faces Challenges from Global Trade Policies. - AInvest
Chardan Capital Maintains Neutral Rating for Outlook Therapeutics with $3.00 Price Target - AInvest
Outlook Therapeutics Reports Q3 2025 Earnings and Milestones - MSN
Outlook Therapeutics Posts Another Loss in Q3 2025 Earnings — Market Impact Remains Mixed - AInvest
Navigating Trade Turbulence: Outlook Therapeutics’ Struggle with Global Trade Policies - The Globe and Mail
What makes Outlook Therapeutics Inc. stock attractive today2025 Major Catalysts & AI Enhanced Trading Signals - sundaytimes.kr
Outlook Therapeutics Inc. Sees Relief Buying After Extended DropJuly 2025 Retail & Free Fast Entry Momentum Trade Alerts - metal.it
Published on: 2025-08-16 19:04:04 - metal.it
Outlook Therapeutics: Pivoting from R&D to Commercialization with LYTENAVA™ in Europe and FDA Approval on Horizon - AInvest
Outlook Therapeutics (OTLK) Maintains Rating by Chardan Capital - GuruFocus
Chardan Capital raises Outlook Therapeutics' PT to $3, maintains Neutral rating. - AInvest
Outlook Therapeutics shares rise 4.12% premarket after reporting financial results for the third quarter. - AInvest
Outlook Therapeutics Posts Q3 Revenue of $1.5mln, Meeting Estimates, and First-Ever Commercial Sales in Europe. - AInvest
Outlook Therapeutics Inc Reports Q3 2025 Earnings: EPS of -$0.55 - GuruFocus
Outlook Therapeutics Q3 FY2025 Financial Results and Corporate Update - TradingView
Outlook Therapeutics reports Q3 adjusted EPS (44c) vs. (83c) last year - TipRanks
Outlook Therapeutics at a Strategic Inflection Point: Regulatory and Commercial Catalysts for Value Creation in the $4B+ Anti-VEGF Market - AInvest
Outlook Therapeutics reports Q3 net loss of $20.2mln, $1.5mln revenue. - AInvest
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewswire
Outlook's Eye Drug LYTENAVA Launches in Europe as Critical FDA Decision Approaches - Stock Titan
Will Outlook Therapeutics Inc. Hold Gains Into CloseEntry Point & Community Verified Watchlist Alerts - kangso.co.kr
Reversal Traders Monitor Outlook Therapeutics Inc. for EntryChart Breakout Buy Signal Detection Confirmed - 선데이타임즈
Outlook Therapeutics, Inc. shares rise 1.94% after-hours due to positive market sentiment. - AInvest
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Outlook Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024OTLK - ACCESS Newswire
Outlook Therapeutics Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
Published on: 2025-08-04 15:25:16 - metal.it
What are analysts’ price targets for Outlook Therapeutics Inc. in the next 12 monthsUnlock high-yield investment opportunities - Jammu Links News
What institutional investors are buying Outlook Therapeutics Inc. stockTriple-digit profit margins - Jammu Links News
What are the latest earnings results for Outlook Therapeutics Inc.Game-changing capital returns - Jammu Links News
What is the dividend policy of Outlook Therapeutics Inc. stockFree Capital Allocation Plans - Jammu Links News
How volatile is Outlook Therapeutics Inc. stock compared to the marketExceptional portfolio growth - Jammu Links News
When is Outlook Therapeutics Inc. stock expected to show significant growthExplosive portfolio gains - Jammu Links News
Is Outlook Therapeutics Inc. a good long term investmentUnrivaled growth potential - Jammu Links News
How strong is Outlook Therapeutics Inc. company’s balance sheetCapitalize on fast-growing stocks today - Jammu Links News
What is the risk reward ratio of investing in Outlook Therapeutics Inc. stockFree Stock Chart Pattern Guide - Jammu Links News
What makes Outlook Therapeutics Inc. stock price move sharplyInvest confidently with expert support - Jammu Links News
What catalysts could drive Outlook Therapeutics Inc. stock higher in 2025Achieve breakthrough performance in the market - Jammu Links News
Should I hold or sell Outlook Therapeutics Inc. stock in 2025Capitalize on emerging market sectors - Jammu Links News
How does Outlook Therapeutics Inc. generate profit in a changing economyAchieve triple-digit returns with smart investing - Jammu Links News
What is Outlook Therapeutics Inc. company’s growth strategyPre Market Recommendation With Low Risk - Jammu Links News
Outlook Therapeutics, Inc. shares rise 1.95% premarket after Eli Lilly's Mounjaro shows heart benefits in a head-to-head study. - AInvest
What institutions are buying Outlook Therapeutics Inc. stock nowEntry Points For Growing Stocks Identified by Models - metal.it
Ichimoku Cloud Indicates Uncertainty Around Outlook Therapeutics Inc.Real Trader Watchlist of Hot Stocks Released - metal.it
0.94%
1.72%
大文字化:
|
ボリューム (24 時間):